103 Despite significant advancements in medical technology and public health initiatives, the early detection of colon cancer remains a complex challenge, according to a recent study published in the World Journal of Gastroenterology. The study, led by researchers Valeria Tonini and Manuel Zanni, delves into the multifaceted reasons behind the continued difficulties in effectively screening for and diagnosing colorectal cancer (CRC) at an early stage. Colorectal cancer is the third most common cancer in men and the second most common in women worldwide, with nearly two million new cases diagnosed annually. Early detection is crucial as it significantly improves patient prognosis and reduces treatment costs. However, the study highlights that despite the implementation of various screening programs, the effectiveness of these initiatives remains suboptimal. The rise in the number of cancer survivors, due to both an ageing population and advancements in cancer treatment, underscores the necessity for early detection strategies. According to the study, the number of cancer survivors in the United States alone is projected to increase by 24.4% by 2032, reaching 22.5 million. This surge in survivorship necessitates improved screening methods to manage the growing volume of patients effectively. One of the critical findings of the study is that the biological heterogeneity of CRC and its dynamic progression pose significant hurdles to early detection. The current screening tests, including colonoscopy, faecal immunochemical tests (FIT), and multi-target stool DNA tests, have limitations in sensitivity and specificity. These limitations result in missed lesions, overdiagnosis, and interval cancers, which undermine the potential benefits of CRC screening. The invasive nature of procedures like colonoscopy also deters patient participation. Psychological and emotional factors, societal disparities, and healthcare accessibility issues further complicate the landscape of CRC screening. The COVID-19 pandemic has exacerbated these challenges by delaying screening processes and reducing participation rates. The study also addresses the issue of early-onset CRC, which has become a significant concern, particularly among younger adults. Most current screening guidelines are tailored for individuals over 50, yet a substantial number of early-onset CRC cases occur in patients younger than 45. This discrepancy means that lowering the screening age might not sufficiently benefit the younger population who fall outside the high-risk categories defined by existing algorithms. Despite these challenges, there is room for optimism. Advances in artificial intelligence and machine learning are paving the way for more refined screening algorithms and risk stratification models. These technologies hold promise for identifying high-risk populations and developing personalised interventions that could enhance the efficacy of CRC screening programs. Moreover, the study emphasises the importance of public health campaigns and culturally sensitive education to improve patient compliance and participation rates. Collaborations between medical professionals, researchers, policymakers, and the public are crucial in overcoming the barriers to effective screening. Early detection not only improves patient outcomes but also has significant economic benefits. Diagnosing CRC at an early stage reduces the need for extensive surgical interventions, lengthy hospital stays, and expensive treatments such as chemotherapy and biologic drugs. In contrast, advanced CRC requires more intensive and costly interventions, including high-cost drugs and various therapeutic techniques to manage the disease. The study argues that investing in early detection strategies could lead to substantial cost savings in the long term.